Skip to main content
SpringerLink
Log in

Oxidized LDL autoantibodies are related to apolipoprotein E phenotype, independently of postprandial change in plasma triglycerides and LDL size, among patients with angiographically verified coronary artery disease and healthy controls

  • Original Paper
  • Published:
Journal of Biomedical Science

Abstract

Objective: Oxidized low-density liporotein (LDL) autoantibodies (oxLDLab), apolipoprotein E (apoE) phenotype, postprandial triglyceride changes and LDL size are suggested to be risk factors for coronary artery disease (CAD). Our aim was to study the interaction between these new risk factors among patients with CAD and healthy controls.Methods: oxLDLab from 31 men with angiographically verified CAD and 31 healthy men were analyzed by enzyme-linked immunosorbent assay. Iso-electric focusing and immunoblotting were used for apoE phenotyping. Triglyceride level was measured after 12 h of fasting and 3, 5 and 7 h after a high-fat meal. Nondenaturing gradient gel electrophoresis was used to separate LDL particles according to size.Results: oxLDLab levels increased according to apoE phenotype in the following order: E2<E3<E4 (p=0.004, ANOVA). The postprandial response of triglycerides, the size of LDL particles and the concentration of LDL and high-density lipoprotein (HDL) cholesterol did not differ between apoE phenotypes, and the use of these variables as covariates did not change the statistically significant difference in oxLDLab levels between apoE phenotypes (p=0.01, ANCOVA). oxLDLab levels did not differ between the patient and control groups.Conclusion: We found an association between apoE allele ɛ2 and decreased levels of oxLDLab, which was independent of the postprandial response of triglycerides, the size of LDL particles and plasma LDL and HDL cholesterol levels. The mechanism by which apoE affects oxidation of LDL remains unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2:200–207;2000.

    Google Scholar 

  2. Ayaori M, Ishikawa T, Yoshida H, Suzukawa M, Nishiwaki M, Shige H, Ito T, Nakajima K, Higashi K, Yonemura A, Nakamura H. Beneficial effects of alcohol withdrawal on LDL particle size distribution and oxidative susceptibility in subjects with alcohol-induced hypertriglyceridemia. Arterioscler Thromb Vasc Biol 17:2540–2547;1997.

    Google Scholar 

  3. Bakalova R, Zhelev Z, Goudev A, Ribarov S, Nachev C. Serum level of IgG autoantibodies against oxidized low density lipoproteins and lag-phase of serum oxidation in coronary heart disease — inverse correlation. Gen Physiol Biophys 18:87–97;1999.

    Google Scholar 

  4. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: An overview. Free Radic Biol Med 28:1815–1826;2000.

    Google Scholar 

  5. Dallongeville J, Tiret L, Visvikis S, O'Reilly DS, Saava M, Tsitouris G, Rosseneu M, DeBacker G, Humphries SE, Beisiegel U. Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: The EARS II study. European Atherosclerosis Research Study. Atherosclerosis 145:381–388;1999.

    Google Scholar 

  6. Dart A, Sherrard B, Simpson H. Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease. Atherosclerosis 130:161–170;1997.

    Google Scholar 

  7. Dart AM, Cooper B. Independent effects of Apo E phenotype and plasma triglyceride on lipoprotein particle sizes in the fasting and postprandial states. Arterioscler Thromb Vasc Biol 19:2465–2473;1999.

    Google Scholar 

  8. Enbergs A, Burger R, Reinecke H, Borggrefe M, Breithardt G, Kerber S. Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: Angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy. Eur Heart J 21:45–52;2000.

    Google Scholar 

  9. Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Yla-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20:204–209;2000.

    Google Scholar 

  10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502;1972.

    Google Scholar 

  11. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20:703–707;2000.

    Google Scholar 

  12. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, Harats D. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138:147–152;1998.

    Google Scholar 

  13. George J, Harats D, Bakshi E, Adler Y, Levy Y, Gilburd B, Shoenfeld Y. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 68:263–266;1999.

    Google Scholar 

  14. Haffner SM, Stern MP, Miettinen H, Robbins D, Howard BV. Apolipoprotein E polymorphism and LDL size in a biethnic population. Arterioscler Thromb Vasc Biol 16:1184–1188;1996.

    Google Scholar 

  15. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 201:1567–1574;1994.

    Google Scholar 

  16. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intimamedia thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21:101–107;2001.

    Google Scholar 

  17. Jansen H, Ghanem H, Kuypers JH, Birkenhager JC. Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B. Atherosclerosis 115:255–262;1995.

    Google Scholar 

  18. Jolivalt C, Leininger-Muller B, Bertrand P, Herber R, Christen Y, Siest G. Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Radic Biol Med 28:129–140;2000.

    Google Scholar 

  19. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 82:67U-73U,discussion 85U–86U; 1998.

    Google Scholar 

  20. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, Yla-Herttuala S, Luoma JS, Koivula T, Nikkari T. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19:23–27;1999.

    Google Scholar 

  21. Lehtimäki T, Moilanen T, Viikari J, Akerblom HK, Ehnholm C, Ronnemaa T, Marniemi J, Dahlen G, Nikkari T. Apolipoprotein E phenotypes in Finnish youths: A cross-sectional and 6-year follow-up study. J Lipid Res 31:487–495;1990.

    Google Scholar 

  22. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 90:165–172;1999.

    Google Scholar 

  23. Makimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenpera S, Syvanne M, Mantysaari M, Summanen P, Bergholm R, Taskinen MR, Yki-Jarvinen H. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 22:973–981;1999.

    Google Scholar 

  24. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49:1033–1041;2000.

    Google Scholar 

  25. Miyata M, Smith JD. Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14:55–61;1996.

    Google Scholar 

  26. Nicoletti A, Caligiuri G, Hansson GK. Immunomodulation of atherosclerosis: Myth and reality. J Intern Med 247:397–405;2000.

    Google Scholar 

  27. Nikkila M, Solakivi T, Lehtimaki T, Koivula T, Laippala P, Astrom B. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease. Atherosclerosis 106:149–157;1994.

    Google Scholar 

  28. Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: A nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48:1454–1458;1999.

    Google Scholar 

  29. Paiker JE, Raal FJ, von Arb M. Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem 37:174–178;2000.

    Google Scholar 

  30. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247:371–380;2000.

    Google Scholar 

  31. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154:2605–2609;1994.

    Google Scholar 

  32. Saarelainen S, Lehtimaki T, Nikkila M, Solakivi T, Nieminen MM, Jaakkola O. Association between apolipoprotein E alleles and autoantibodies against oxidised low-density lipoprotein. Clin Chem Lab Med 38:477–478;2000.

    Google Scholar 

  33. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148:171–177;2000.

    Google Scholar 

  34. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, Visvikis S. Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clin Chem 41:1068–1086;1995.

    Google Scholar 

  35. Smith JD, Miyata M, Poulin SE, Neveux LM, Craig WY. The relationship between apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int J Clin Lab Res 28:116–121;1998.

    Google Scholar 

  36. van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122:245–253;1996.

    Google Scholar 

  37. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785–1792;1991.

    Google Scholar 

  38. Zhao SP, Verhoeven MH, Vink J, Hollaar L, van der Laarse A, de Knijff P, van't Hooft FM. Relationship between apolipoprotein E and low density lipoprotein particle size. Atherosclerosis 102:147–154;1993.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Atherosclerosis Genetics, Centre for Laboratory Medicine, Tampere, Finland

    Saara Metso MD, Olli Jaakkola, Tiina Solakivi & Terho Lehtimäki

  2. Department of Internal Medicine, Tampere University Hospital, PO Box 2000, FIN-33521, Tampere, Finland

    Saara Metso MD

  3. Department of Internal Medicine, City Hospital of Tampere, Tampere, Finland

    Matti Nikkilä

  4. School of Public Health, University of Tampere, and Research Unit, Tampere University Hospital, Tampere, Finland

    Pekka Laippala

  5. Department of Medical Biochemistry, Medical School, University of Tampere, Tampere, Finland

    Olli Jaakkola & Tiina Solakivi

Authors
  1. Saara Metso MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matti Nikkilä
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pekka Laippala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olli Jaakkola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tiina Solakivi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Terho Lehtimäki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Metso, S., Nikkilä, M., Laippala, P. et al. Oxidized LDL autoantibodies are related to apolipoprotein E phenotype, independently of postprandial change in plasma triglycerides and LDL size, among patients with angiographically verified coronary artery disease and healthy controls. J Biomed Sci 10, 345–351 (2003). https://doi.org/10.1007/BF02256454

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02256454

Key Words

Search

Navigation